The China Biotech Landscape – Opportunities in China and the Path to USFDA Approval
Download your data- and analysis- packed white paper from Scrip, presented in partnership with Novotech. You will get an inside look at:
- Regulatory clinical development options in the US, including advantages and challenges for Chinese firms wishing to enter the US market
- Regulatory clinical development options in China, including advantages and challenges for Western biopharma companies in China
- Key attributes to an ideal CRO partner
- And more